EcoDrugPlus

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMZEG00005025120
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3

Ensembl ID : ENSMZEG00005027202
Gene Symbol: LOC101465105
3 Cross references
206 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3

Ensembl ID : ENSMZEG00005008727
Gene Symbol: LOC106675270
2 Cross references
208 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSMZEG00005011947
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSMZEG00005023745
Gene Symbol: LOC101472021
3 Cross references
219 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A

Ensembl ID : ENSMZEG00005013516
Gene Symbol: LOC101470553
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSMZEG00005017097
Gene Symbol: RARB
4 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSMZEG00005015774
Gene Symbol: LOC101478141
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSMZEG00005027189
Gene Symbol: RARG
4 Cross references
353 Possible Orthologues:

Retinoic Acid Receptor Gamma-A

Ensembl ID : ENSMZEG00005001619
Gene Symbol: LOC101468354
3 Cross references
377 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSMZEG00005015929
Gene Symbol: RXRA
3 Cross references
225 Possible Orthologues:

Rho-Associated Protein Kinase 2

Ensembl ID : ENSMZEG00005018234
Gene Symbol: LOC101470679
3 Cross references
225 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).